Reviews/Chronic Spontaneous Urticaria Treatment/Omalizumab 300mg for refractory chronic spontaneous urticaria
Omalizumab · CSU-OMA-01 · v2
The evidence here consistently shows that the licensed dose of omalizumab reduces hives and itch in patients whose chronic spontaneous urticaria is not controlled by antihistamines. Two large placebo-controlled trials [1][16] and a comparator arm in a third [3] all point the same way, and two real-world patient cohorts [6][12] report that roughly two-thirds of patients get complete or near-complete relief at the standard dose. The main caveat the panel noted is that this control is not universal: only a minority reach total clearance, and a sizeable share of patients do not respond at all [15]. The panel read the claim as asserting symptom control rather than complete remission for everyone, and found that reading firmly supported by the corpus. The disagreement in the record was about how complete the control is, not about whether the drug works.
Two independent phase 3 placebo-controlled RCTs show omalizumab 300mg significantly reduces itch and urticaria activity versus placebo, with [16] reporting UAS7<=6 in 51.9% versus 11.3% and a weekly itch-severity score reduction of 5.80 points (P<0.0001), and [1] showing a change of -9.8 versus -5.1 (P<0.001). A third RCT [3] shows 26% of the omalizumab 300mg arm achieving complete symptom control versus 0% on placebo. Two retrospective real-world cohorts converge at the licensed dose, with 67% complete or almost-complete response in [6] and 65% reaching UAS7od<=6 in [12]. Against this, complete clearance is a minority outcome (UAS7=0 in 35.8% in [16]) and [15] estimates roughly 30% of patients do not respond to the standard regimen. The contested point: The division is over completeness, not direction: the Synthesist treats partial, fractional control as sufficient for a 'controls symptoms' claim, while the Sceptic stresses that complete response is a minority (35.8% in [16], 26% in [3]) and that roughly 30% are non-responders [15]. There is also contention over whether retrospective cohorts [6][12] inflate response above the RCT-measured rate.
All 16 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Spontaneous Urticaria Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
"Controls symptoms" overstates completeness: complete response (UAS7=0) is only 35.8% in ASTERIA I [16] and 26% in [3], and [15] reports ~30% non-response to the standard 300mg regimen, so control is partial and population-fractional, not universal.
The pivotal RCTs [1][16] are manufacturer-funded (Genentech/Novartis) and [3]'s omalizumab arm sits inside a competitor-sponsored trial, introducing risk of sponsorship bias.
Where it remains uncertain. Complete response is a minority (UAS7=0 in 35.8% in [16]; 26% in [3]) and roughly 30% of patients do not respond to the standard regimen [15], so control is population-fractional.
Aleatory
Response varies across patients, from complete clearance to non-response, reflecting biological variation within the population [12][15].
Epistemic
The corpus reports symptom control over 12-24 weeks but little on lasting remission; [15] notes lack of remission at 6 months in a quarter of patients.
Inferential
Retrospective cohorts use physician-assessed, non-validated instruments [6], so 65-67% completion rates may not be comparable to RCT UAS7 endpoints.
The load-bearing papers from a corpus of 16, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal phase 3 RCT establishing dose-dependent, statistically significant symptom reduction at 300mg in the exact refractory population.
“At week 12, the mean (±SD) change from baseline in the weekly itch-severity score was -5.1±5.6 in the placebo group, -5.9±6.5 in the 75-mg group (P=0.46), -8.1±6.4 in the 150-mg group (P=0.001), and -9.8±6.0 in the 300-mg group (P<0.001).”
Panel auditInternal validity: high · scope of inference: Adults with moderate-to-severe CIU/CSU remaining symptomatic on licensed-dose H1-antihistamines, 12-week itch outcome.Key limitations: itch score is one symptom dimension · 16-week horizon · industry funded
Third RCT corroborating that omalizumab 300mg delivers complete symptom control in a quarter of patients versus none on placebo.
“At week 12, a total of 30%, 44%, and 40% of the patients treated with 24 mg, 72 mg, and 240 mg, respectively, of ligelizumab had complete control of symptoms, as compared with 26% of the patients in the omalizumab group and no patients in the placebo group.”
Panel auditInternal validity: medium · scope of inference: Complete control of hives/symptoms at week 12 in moderate-to-severe CSU inadequately controlled on H1-antihistamines.Key limitations: omalizumab arm not the primary comparison · no p-value for omalizumab vs placebo · complete-control endpoint is stringent
Real-world cohort confirming high complete/almost-complete response rates at the licensed dose outside trial conditions.
“A total of 67% of patients with CSU responded completely or almost completely to treatment; 22% responded partially, whereas 10% had no or limited response to treatment.”
Panel auditInternal validity: low · scope of inference: Routine-care effectiveness of omalizumab in CSU/CINDU at a tertiary centre.Key limitations: retrospective · no control arm · non-validated response grading · doses pooled
Mean Urticaria Activity Score declined significantly from baseline during omalizumab treatment (P=.0002).
Panel auditInternal validity: low · scope of inference: Antihistamine-resistant chronic autoimmune urticaria treated with individualized-dose omalizumab.Key limitations: n=12 · CAU subtype not CSU generally · dose not fixed 300 mg · no parallel control
4 of 16 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple concordant phase 3 RCTs plus consistent real-world data on the exact dose and population establish symptom control, with magnitude tempered only by the partial, fractional nature of response.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Durability of symptom control beyond 24 weeks. All scored RCTs measure to 12-24 weeks; whether control persists or relapses on continued dosing is unestablished, and [15] flags non-remission at 6 months. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A long-term prospective cohort or extension RCT tracking UAS7 on maintenance 300mg dosing over 12+ months with defined relapse endpoints.
Open question: Does symptom control at the 300mg dose persist beyond 6 months, or do patients relapse on continued treatment? Why it is still open: Scored trials end at 12-24 weeks and [15] reports a quarter of patients on a second course with apparent non-remission at 6 months.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19